Eye Drops Manufacturing Project Report: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue

Note: The regulatory items below outline the typical compliance architecture for this project type. Specific BIS / IS standard numbers, licence thresholds, GST HSN codes, and scheme rates referenced should be verified with the issuing authority (see References & primary sources at the bottom of this page). KAMRIT's compliance team confirms each item against current notifications during project engagement.

Eye drops manufacturing in India operates under a multi-layered regulatory architecture where CDSCO manufacturing licence is the primary authorisation, supplemented by Schedule M compliance, BIS primary packaging standards, and environmental clearances that collectively span 14-18 months for greenfield approval.

• CDSCO Form 27 or Form 27B manufacturing licence under Drugs and Cosmetics Act 1940 and Rules 1945, depending on whether the facility is for domestic sale only or includes export to regulated markets. Application submitted via SUGAM portal with detailed plant layout, equipment schedule, and quality control protocols.
• Schedule M and Schedule M-III (revised) compliance for sterile pharmaceutical products, mandating ISO Class 7 aseptic areas, environmental monitoring programmes, and validation protocols for each product SKU. Mock recall procedures and pharmacovigilance obligations under D&C Act Rule 122D.
• BIS IS 5867 (Parts 1 and 2) conformance for LDPE containers intended for packing drinking water and pharmaceutical preparations, including dropper bottles. Polymer resin sourcing must be from BIS-certified suppliers with batch-wise COA documentation.
• EIA Notification 2006 and subsequent amendments for pharma greenfield projects with capex above ₹100 crore, requiring public consultation and MoEF&CC environmental clearance. Projects below ₹100 crore submit consent to establish under state Pollution Control Board (PCB) rules.
• GST registration under GSTN with HSN code 3004 for medicaments including ophthalmic preparations, with input tax credit chain maintained through raw material procurement to finished goods dispatch. GST compensation cess does not apply to ophthalmic formulations.
• Drug Licence Number (DLN) from state drugs controller upon successful inspection by CDSCO zonal officer, valid for five years with annual renewal of fee and periodic Schedule M compliance audit. USFDA or WHO-GMP certification adds export eligibility.
• MSME Udyam registration for entities with CapEx below ₹250 crore, unlocking access to CGTMSE collateral-free credit guarantees, PMEGP subsidies for first-generation entrepreneurs, and state pharmaceutical park incentives in Gujarat, Maharashtra, and Telangana.
• ALMM (Approved List of Models and Manufacturers) does not apply to pharma manufacturing; however, PLI Scheme for Bulk Drugs and Medical Devices (expanded in PLI 2.0) applies if the project includes ophthalmic API synthesis, with incentive rates of 5-10% on incremental sales for selected products including chloramphenicol and dexamethasone intermediates.

KAMRIT Financial Services LLP manages the full approvals lifecycle from SUGAM portal submission through CDSCO inspection coordination, state drugs controller licensing, and PCB consent, providing promoters with a single-window regulatory milestone tracker across the 14-18 month approval timeline.

Ophthalmic solutions, specifically eye drops, constitute a distinct sub-segment within Indian pharma, differentiated from oral solids and parenterals by aseptic manufacturing imperatives, primary container specifications (LDPE ophthalmic bottles, sterile_filters, and dropper assemblies), and a prescription-to-OTC transition tailwind. Within the ₹43,824 crore ophthalmic market, anti-infective eye drops hold approximately 28% share, lubricating or artificial tears represent 24% with fastest growth (14.2% CAGR driven by digital eye strain), anti-inflammatory drops command 18%, and glaucoma therapeutics occupy 15% with chronic therapy stickiness. The remaining 15% spans anti-allergic, combination steroid-antibiotic, and preservative-free formulations targeting premium ophthalmology clinics.

Hospital procurement channels account for 35% of volumes, institutional supply to government NMBI and state health missions contributes 22%, while retail pharmacy distribution through 850,000+ outlets represents 43%. The D2C-first brand has disrupted traditional distribution by capturing 8-12% of premium lubricating drops through e-pharmacy and own-platform sales at 340-380% retail mark-ups. US generics export opportunity centres on Abbreviated New Drug Applications (ANDAs) for generic drops facing patent expiry, with US market value exceeding USD 2.8 billion annually.

The private equity-backed national chain has invested ₹380 crore in ophthalmic manufacturing expansion over 2023-2025, signalling institutional conviction in the sub-sector's growth runway.

Project-specific demand drivers

• PLI Bulk Drug and Medical Devices
• US generics export opportunity
• Health insurance penetration rising
• Chronic disease burden growth
• Hospital capex expansion in Tier-2/3

Eye drops manufacturing technology centres on Blow-Fill-Seal (BFS) aseptic processing, which has replaced terminal sterilisation as the dominant technology for ophthalmic liquids in India due to superior particle/contamination control. Leading BFS equipment suppliers include Rommelag (Germany) offering 3,600-7,200 containers per hour capacity per station, with UNISEAL and IMA (Italy) serving the mid-market. For projects targeting ₹12.8-45 crore CapEx, a single-line BFS system with 60,000 units per day capacity costs ₹6.5-12 crore installed, requiring 450-600 sqm of classified space.

Multi-line facilities targeting ₹233 crore CapEx deploy 3-4 parallel BFS lines with combined throughput of 200,000+ units per day and integrated visual inspection systems (like Brevetti CEA or Antares Vision) costing ₹35-55 crore per line. Primary containers demand LDPE resin conforming to IS 5867, with ophthalmic-grade resin priced at ₹145-165 per kg. The cleanroom HVAC and air handling system constitutes 18-22% of total equipment capex, with energy consumption of 380-450 kW for a 60,000 units per day facility.

Sterile filtration through 0.22-micron membrane filters (Pall, Merck Millipore) requires batch validation at ₹2.5-4 lakh per filter type per product. Water for injection (WFI) generation via double-pass RO and still costs ₹45-75 lakh per unit with annual maintenance of ₹8-12 lakh. Conversion cost per ml of finished product is ₹0.85-1.40 for a mid-sized facility, reducing to ₹0.55-0.75 at 85% capacity utilisation above 150,000 units per day.

Chinese BFS equipment from suppliers like Zhenjiang has entered the sub-₹5 crore installed cost segment but carries GMP compliance risk and limited after-sales service, limiting adoption among CDSCO-inspected facilities targeting regulated exports.

For a eye drops manufacturing project at ₹12.8 crore - ₹233 crore CapEx with a 3.6 - 6.2-year payback, the bank-loan-ready Means of Finance KAMRIT recommends is 30-40% promoter equity and 60-70% debt. The primary lender pool for this scale is SBI MSME, Bank of Baroda, HDFC Bank, ICICI Bank, Axis Bank term loans plus working capital facilities. The applicable overlay schemes that materially compress effective cost-of-capital are CGTMSE up to ₹5 cr, PLI sector overlay where eligible, state capital subsidy. The Tier 2 Bankable DPR includes the full vendor-quote-backed CapEx schedule, OpEx model, 5-year revenue projection split by SKU and channel, working-capital cycle, ROI/NPV/IRR, break-even, and sensitivity in three scenarios (base / bull / bear). The model is structured for direct submission to a commercial bank or NBFC credit appraisal team.

For eye drops manufacturing at ₹12.8 crore - ₹233 crore CapEx and 3.6 - 6.2-year payback, the three risks KAMRIT structures mitigation around are demand-side execution risk, input-cost volatility, and regulatory-delay risk. For this category specifically, KAMRIT also models supplier concentration risk, currency exposure where input-imports exceed 25 percent of CapEx, and the working-capital cycle stretch in the first 18 months of commissioning. The Bankable DPR contains the full three-scenario sensitivity (base / bull / bear) on revenue, gross margin, and CapEx that a credit committee needs to see.